– USA, NJ – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Keith Woods to its Board as an Independent Non-Executive Director.
“I’m thrilled to welcome Keith to our Board of Directors, who brings deep industry expertise and invaluable experience to the Rocket Board as we build upon our commercial and operational infrastructure to support our anticipated first product launches for severe Leukocyte Adhesion Deficiency (LAD-I) and Fanconi Anemia (FA),” said CEO, Dr. Gaurav Shah “Keith’s hands-on experience advancing a highly successful, global biotech company from clinical to commercial stage and successfully launching products across multiple geographies will be a tremendous asset as we develop and prepare to deliver gene therapies from our world-class pipeline to patients with devastating hematologic and cardiovascular conditions.”
About R. Keith Woods
Keith Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy, and supply chain.
Mr. Woods most recently served as COO of argenx, where he led its global commercial organization, including marketing, market access, medical affairs, program management, and supply chain, during the company’s successful transition to the commercial stage. He helped launch Vyvgart, a treatment for a rare autoimmune condition that causes muscle weakness, generating more than $1 billion in sales. Before argenx, Mr. Woods was SVP of North American Business Operations at Alexion Pharmaceuticals, where he oversaw the U.S. and Canadian business and was responsible for more than $1 billion in annual sales. He previously served as VP and Managing Director of Alexion UK, VP of U.S. Commercial Operations, and Executive Director of Sales, leading the launch of Soliris in atypical hemolytic uremic syndrome.
“It is an honor to join Rocket’s Board at this critical time, as the company prepares to launch its first potential gene therapy for a rare disease,” said Mr. Woods. “I have admired Rocket’s innovative science across its hematology and cardiovascular portfolios and look forward to working closely with Rocket leadership to help the company realize its full potential through the expected transition from R&D to commercial stage.”
Mr. Woods serves as an advisor to the Board of Directors at argenx and is a member of the Board of Directors at both X4 Pharmaceuticals and TScan Therapeutics. Earlier in his career, Mr. Woods held commercial and sales positions of increasing responsibility at Roche, Amgen, and Eisai. Mr. Woods holds a Bachelor of Science degree in Marketing from Florida State University.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral (LV) vector-based gene therapy are for the treatment of Fanconi Anemia, a difficult-to-treat genetic disease that leads to bone marrow failure and potential cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency, a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also is developing AAV-based gene therapy programs in PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
SOURCE: https://rocketpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.